Olema Pharmaceuticals (OLMA) Receives Buy Rating with $45 Price Target
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 07 2026
0mins
Source: Yahoo Finance
- Rating Analysis: Olema Pharmaceuticals has received a buy rating with an average price target of $45, which may enhance investor confidence and potentially drive the stock price upward.
- Market Outlook: As the pharmaceutical industry continues to grow, Olema's product line and R&D advancements could attract more investor attention, thereby increasing its market valuation.
- Investor Confidence: The buy rating from analysts indicates an optimistic outlook on Olema's future performance, which may draw in more institutional investors and further boost the stock price.
- Strategic Implications: The $45 price target reflects market recognition of Olema's growth potential, which could encourage the company to increase R&D investments to capture a larger market share.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like OLMA with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on OLMA
Wall Street analysts forecast OLMA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for OLMA is 42.00 USD with a low forecast of 20.00 USD and a high forecast of 60.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
11 Analyst Rating
11 Buy
0 Hold
0 Sell
Strong Buy
Current: 24.570
Low
20.00
Averages
42.00
High
60.00
Current: 24.570
Low
20.00
Averages
42.00
High
60.00
About OLMA
Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. It is advancing a pipeline of novel therapies by leveraging its deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Its lead product candidate, palazestrant (OP-1250), is a proprietary, orally available complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD), in a Phase 3 clinical trial called OPERA-01. It is being investigated in patients with recurrent, locally advanced or metastatic ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. In addition, it is developing OP-3136, a potent KAT6 inhibitor, in a Phase 1 clinical trial. OP-3136 is a novel, orally available small molecule that potently and selectively inhibits KAT6.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Glaukos Corp (GKOS) Projects FY25 Sales of $507 Million, Shares Drop 12.1%
- Glaukos Sales Projection: Glaukos Corp anticipates FY25 sales of $507 million, yet its shares fell 12.1% in pre-market trading, indicating market concerns about its growth outlook despite the positive sales forecast.
- Briacell's Sharp Decline: Briacell Therapeutics' announcement of a $30 million public offering led to a staggering 53.1% drop in its stock price during pre-market trading, reflecting investor apprehension regarding the financing strategy.
- Trip.com Investigation Impact: Trip.com Group confirmed it is under investigation by China's SAMR for potential anti-monopoly violations, resulting in a 9.3% decline in its pre-market stock price, which may adversely affect its market performance and investor confidence.
- Pearson Trading Update: Pearson PLC's trading update for 2025 caused its shares to drop 7.2% in pre-market trading, indicating a cautious market sentiment regarding its future performance.
Continue Reading
Olema Pharmaceuticals Board Member Sells 264,800 Shares for $7.9 Million
- Complete Equity Exit: Olema Pharmaceuticals board member Ian T. Clark executed a disposition of 264,800 shares through option exercise and immediate sale, totaling $7.9 million, marking a complete exit from direct equity holdings with both direct and indirect ownership now at zero.
- Option-Driven Transaction: The transaction was executed through the exercise of options followed by an immediate sale, indicating that the entire event was driven by option-related mechanics rather than an open-market disposition of long-held equity.
- Strong Stock Performance: The weighted average sale price of $29.73 per share was 7.5% above the market close of $27.93 on December 19, reflecting a monetization opportunity after a remarkable 326.50% stock surge over the past year.
- Stable Financial Position: Despite Olema's R&D spending rising to $40 million in Q3 and a net loss widening to $42.2 million, the company maintains $329 million in cash and marketable securities, ensuring operational runway into 2028.
Continue Reading